$2.6 B

IRWD Mkt cap, 20-Sep-2018

$150.3 M

Ironwood Pharmaceuticals Revenue Q2, 2018
Ironwood Pharmaceuticals Net income (Q2, 2018)-92.5 M
Ironwood Pharmaceuticals EBIT (Q2, 2018)-75.8 M
Ironwood Pharmaceuticals Cash, 30-Jun-2018145.4 M
Ironwood Pharmaceuticals EV2.5 B

Ironwood Pharmaceuticals Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

22.9 m76.4 m149.6 m274 m

Revenue growth, %

234%96%83%

R&D expense

139.5 m

General and administrative expense

173.3 m

Operating expense total

312.8 m

EBIT

(252 m)(169.4 m)(102.1 m)(51.9 m)

EBIT margin, %

(1101%)(222%)(68%)(19%)

Interest expense

39.2 m

Net Income

(272.8 m)(189.6 m)(142.7 m)(81.7 m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

52.2 m65.1 m86.8 m69.2 m150.3 m

Cost of goods sold

2 m1.9 m10.5 m12 k8.2 m12 k12 k

R&D expense

23 m27.1 m22.1 m25.1 m26.6 m28.6 m25.8 m31.8 m31.7 m37.5 m33.7 m37.3 m37.1 m36.5 m75.4 m

General and administrative expense

30.3 m29.9 m29.3 m28.5 m30.3 m33 m30.4 m36.2 m36.9 m45 m55.6 m57.8 m61.8 m61.9 m127.9 m

Operating expense total

53.3 m57.1 m51.4 m53.7 m57 m61.6 m56.3 m68 m68.6 m82.5 m89.3 m95.1 m98.8 m98.4 m203.3 m

EBIT

(56.6 m)(44.4 m)(55.1 m)(36.7 m)(28.1 m)(42 m)(26.2 m)(2 m)(15.3 m)(28.3 m)(39.7 m)(41 m)(19.4 m)(35.9 m)(75.8 m)

EBIT margin, %

(76%)(63%)(22%)(52%)(50%)

Interest expense

5.3 m5.3 m5.3 m5.3 m5.2 m5.9 m10 m9.9 m9.8 m9.8 m9 m9 m9.1 m9.3 m18.7 m

Net Income

(61.8 m)(49.6 m)(60.4 m)(42 m)(33.2 m)(48 m)(47.4 m)(13.3 m)(21.7 m)(33.2 m)(52.5 m)(44.2 m)(32.3 m)(43.1 m)(92.5 m)

Ironwood Pharmaceuticals Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

75.5 m74.3 m261.3 m54 m

Accounts Receivable

513 k10 k2.9 m933 k

Inventories

6.2 m10.6 m6.3 m1.1 m

Current Assets

229.1 m289.7 m500.2 m380.2 m

PP&E

37.4 m29.8 m21.1 m20.5 m

Goodwill

785 k

Total Assets

279 m333.5 m619.1 m709.8 m

Accounts Payable

10.1 m9.8 m8.6 m17.7 m

Short-term debt

1.1 m1.2 m2.6 m6.2 m

Current Liabilities

41 m60.5 m76.5 m91.1 m

Long-term debt

174.7 m

Total Debt

175.8 m6.2 m

Common Stock

103 k125 k127 k133 k

Additional Paid-in Capital

815.9 m1.1 b1.2 b1.3 b

Retained Earnings

(777.8 m)(967.4 m)(1.1 b)(1.2 b)

Total Equity

38.2 m88.6 m95.1 m66.7 m

Debt to Equity Ratio

4.6 x0.1 x

Debt to Assets Ratio

0.6 x0 x

Financial Leverage

7.3 x3.8 x6.5 x10.6 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

144.5 m205.1 m95.4 m51.3 m63.7 m256.5 m248.1 m280.9 m277.3 m182.9 m133.3 m182.1 m162.6 m144.8 mwdxefcqufszuzezftuxetqsqxt145.4 m

Accounts Receivable

125 k13 k380 k862 k1.1 m2.6 m908 k1.3 m1.2 m1.2 m4 m4.3 m5 m6.7 m

Inventories

20.6 m23.4 m13 m13 m5 m1.5 m1.1 m479 k1.7 m1.1 m

Current Assets

275.8 m371.3 m325.8 m304.1 m263.9 m527 m505.8 m495.7 m386.1 m382.8 m357.9 m341.5 m314.1 m275.7 m279.5 m

PP&E

37.2 m35.5 m33.6 m30.4 m27.5 m25 m23.2 m19.4 m17.9 m18.8 m18.6 m17.9 m17.2 m16.8 m16.3 m

Goodwill

649 k649 k785 k785 k785 k785 k785 k

Total Assets

325.8 m418.9 m371.1 m346.2 m305.5 m653.9 m613.4 m603.3 m700.2 m732 m701.3 m705.1 m625.1 m571.1 m618.2 m

Accounts Payable

2.4 m4.8 m3.4 m6.1 m

Short-term debt

1.1 m1.2 m1.1 m1.1 m1.2 m1.2 m2.3 m2.4 m2.5 m3.5 m5.5 m5.1 m4.4 m3.4 m2.5 m

Current Liabilities

39.7 m38.5 m41.6 m54.1 m59.8 m62.1 m67.8 m78.1 m91 m95.3 m78.9 m80 m64.5 m62.3 m95 m

Long-term debt

174.7 m237.9 m241.5 m245.3 m

Total Debt

175.8 m1.2 m1.1 m1.1 m1.2 m1.2 m2.3 m2.4 m2.5 m3.5 m243.4 m246.6 m249.7 m3.4 m2.5 m

Common Stock

97 k119 k120 k124 k126 k126 k127 k128 k130 k131 k134 k135 k135 k138 k139 k

Additional Paid-in Capital

809.9 m1 b1 b1 b1.1 b1.2 b1.2 b1.2 b1.2 b1.2 b1.3 b1.3 b1.3 b1.3 b1.4 b

Retained Earnings

(725.8 m)(827.5 m)(887.8 m)(929.8 m)(1 b)(1 b)(1.1 b)(1.1 b)(1.1 b)(1.2 b)(1.2 b)(1.3 b)(1.3 b)(1.4 b)(1.4 b)

Total Equity

84.2 m188.9 m141.8 m108.2 m68.2 m140.3 m100.5 m90.9 m81.4 m59.5 m29.6 m4.9 m

Financial Leverage

3.9 x2.2 x2.6 x3.2 x4.5 x4.7 x6.1 x6.6 x8.6 x12.3 x23.7 x144.8 x

Ironwood Pharmaceuticals Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(272.8 m)(189.6 m)(142.7 m)(81.7 m)

Depreciation and Amortization

11.7 m12.3 m11.6 m10.3 m

Accounts Receivable

(1.7 m)(24 m)(29 m)(10.3 m)

Inventories

(52 k)(3.9 m)2.6 m(3.1 m)

Accounts Payable

(11.7 m)1.4 m

Cash From Operating Activities

(273.4 m)(155.6 m)(106.9 m)(25.4 m)

Purchases of PP&E

(9.6 m)(3.5 m)(4 m)(4.2 m)

Cash From Investing Activities

(101.4 m)(56.6 m)

Cash From Financing Activities

313.6 m210.9 m303.1 m(4.2 m)

Interest Paid

18.4 m19.6 m22.7 m24.5 m

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Net Income

(61.8 m)(49.6 m)(60.4 m)(42 m)(33.2 m)(48 m)(47.4 m)(13.3 m)(21.7 m)(33.2 m)(52.5 m)(43.1 m)(92.5 m)

Depreciation and Amortization

1.8 m3.5 m

Accounts Receivable

380 k862 k1.1 m2.6 m908 k1.3 m1.2 m1.2 m11.5 m1.6 m

Inventories

13 m13 m5 m1.5 m(768 k)

Accounts Payable

3.4 m6.1 m

Cash From Operating Activities

(30.9 m)(53.6 m)

Purchases of PP&E

(1.5 m)(3.2 m)

Cash From Investing Activities

44.7 m57.1 m

Cash From Financing Activities

5.3 m17.4 m

Ironwood Pharmaceuticals Ratios

USDY, 2018

EV/EBIT

-33.1 x

EV/CFO

-46.8 x
Report incorrect company information